Cited by 278Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Open access

Blankenhorn, D H, Alaupovic, P, Wickham, E, Chin, H P, Azen, S P·1990·Circulation

DOI 10.1161/01.cir.81.2.470

Open this paper in CoChat — free account Open PDF

Abstract

A within-group risk factor analysis was conducted to predict angiographic change in the Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled trial of colestipol plus niacin therapy in men with previous coronary bypass surgery. Global angiographic change, including both native coronary arteries and bypass grafts after 2 treatment years, was the end point. Risk factors included on-trial clinical measures, plasma lipids, lipoproteins, and apolipoproteins. Univariate analysis indicated that risk factors previously observed by others in epidemiologic investigation of ischemic heart disease--total cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein B, and diastolic blood pressure--had significant effects in the placebo-treated group. Univariate analysis indicated significant effects of apolipoprotein C-III in drug- and placebo-treated groups. Multivariate analysis indicated the predominant risk factor predicting the probability of global coronary progression was non-HDL cholesterol in placebo-treated subjects and the content of apolipoprotein C-III in high density lipoproteins of drug-treated subjects. Both drug- and placebo-treated group findings point to an important role for triglyceride-rich lipoproteins in progression and regression of human atherosclerosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.81.2.470

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
Burstein, M., Scholnick, H. R., & Morfin, R. F. (1970) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42943-8 · Cited by 2,500
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
Self-citation
Sur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérum
Burstein, M., & Samaille, J. (1960) · Clinica Chimica Acta · doi:10.1016/0009-8981(60)90075-9 · Cited by 620
Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis
Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 498

Show all 32 references

Sorted by citations

Items 101–200 of 278

Updates on apolipoprotein CIII
Zheng, C. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000040 · Cited by 51
Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary heart disease — the EARS II study
Tiret, Gerdes, MURPHY, M., Dallongeville, Nicaud, O'Reilly, J., Beisiegel, Backer, D., & On Behalf Of The Ears Group (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00674.x · Cited by 50
Effect of lipoproteins on cultured human mesangial cells
Nishida, Y., Yorioka, N., Oda, H., & Yamakido, M. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90467-4 · Cited by 49
Differential progression of complex and smooth stenoses within the same coronary tree in men with stable coronary artery disease
Chester, M. R., Chen, L., Tousoulis, D., Poloniecki, J., & Kaski, J. C. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00472-3 · Cited by 48
The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease
Kastelein, J. J. P., Groenemeyer, B. E., Hallman, D. M., Henderson, H., Reymer, P. W. A., Gagné, S., Jansen, H., Seidell, J. C., Kromhouf, D., Jukema, J. W., et al. (1998) · Clinical Genetics · doi:10.1111/j.1399-0004.1998.tb02577.x · Cited by 49
Dyslipidemia in Peritoneal Dialysis — Relation to Dialytic Variables
Johansson, A., Samuelsson, O. G., Attman, P., Haraldsson, B. S., Moberly, J. B., Knight‐Gibson, C., & Alaupovic, P. (2000) · Peritoneal Dialysis International · doi:10.1177/089686080002000307 · Cited by 45
Self-citation
Alterations in Lipoprotein Composition in Peritoneal Dialysis Patients
Moberly, J. B., Attman, P., Samuelsson, O. G., Johansson, A., Knight‐Gibson, C., & Alaupovic, P. (2002) · Peritoneal Dialysis International · doi:10.1177/089686080202200209 · Cited by 43
Self-citation
Genetic determinants of cardiometabolic risk: A proposed model for phenotype association and interaction
Blackett, P. R., & Sanghera, D. K. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.079 · Cited by 47
Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: Clinical aspects
Hodis, H. N., Mack, W. J., Krauss, R. M., & Alaupovic, P. (1999) · Clinical Cardiology · doi:10.1002/clc.4960221404 · Cited by 43
Self-citation
Residence Time of Low-Density Lipoprotein in the Normal and Atherosclerotic Rabbit Aorta
Tozer, E. C., & Carew, T. E. (1997) · Circulation Research · doi:10.1161/01.res.80.2.208 · Cited by 43
Characterization of Recombinant Wild Type and Site-Directed Mutations of Apolipoprotein C-III: Lipid Binding, Displacement of ApoE, and Inhibition of Lipoprotein Lipase
Liu, H., Talmud, P. J., Lins, L., Brasseur, R., Olivecrona, G., Peelman, F., Vandekerckhove, J. S., Rosseneu, M., & Labeur, C. (2000) · Biochemistry · doi:10.1021/bi0009441 · Cited by 42
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes
Klein, R. L., McHenry, M. B., Lok, K. H., Hunter, S. J., Le, N., Jenkins, A. J., Zheng, D., Semler, A. J., Page, G. P., Brown, W. V., et al. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.04.005 · Cited by 41
Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins
Marcoux, C., Tremblay, M., Fredenrich, A., Davignon, J., & Cohn, J. S. (2001) · Metabolism · doi:10.1053/meta.2001.19452 · Cited by 41
A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
Ribalta, J., Ville, A. E. L., Vallvé, J.-C., Humphries, S. E., Turner, P. R., & Masana, L. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37189-3 · Cited by 42
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 40
Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity
Bard, J., Charles, M.-A. A., Juhan-Vague, I., Vague, P., André, P., Safar, M. E., Fruchart, J., & Eschwège, É. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.407 · Cited by 39
The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention
Texter, M. J., Lees, R. S., Pitt, B., Dinsmore, R. E., & Uprichard, A. C. G. (1993) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00878518 · Cited by 39
The Atherogenic Significance of an Elevated Plasma Triglyceride Level
Ooi, T. C., & Ooi, D. S. (1998) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408369891234255 · Cited by 37
Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content
Khoo, C., Campos, H., Judge, H., & Sacks, F. M. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33358-7 · Cited by 37
Hypertriglyceridemia: Risks and perspectives
Gotto, A. M. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91086-j · Cited by 37
9 Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease
Hamsten, A. (1990) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80084-9 · Cited by 36
Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45–>Asn), in a Turkish patient.
Lüttmann, S., von Eckardstein, A., Wei, W., Funke, H., Köhler, E., Mahley, R. W., & Assmann, G. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40084-7 · Cited by 35
Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome
Li, L., Zhang, J., Zeng, J., Liao, B., Peng, X., Li, T., Li, J., Tan, Q., Li, X., Yang, Y., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4522 · Cited by 34
Dyslipoproteinemia in diabetic renal failure
Attman, P., Nyberg, G., William-Olsson, T., Knight‐Gibson, C., & Alaupovic, P. (1992) · Kidney International · doi:10.1038/ki.1992.430 · Cited by 34
Self-citation
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele
Olivieri, O., Martinelli, N., Baroni, M., Branchini, A., Girelli, D., Friso, S., Pizzolo, F., & Bernardi, F. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000440 · Cited by 32
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with lipoprotein subclasses
Klein, R. L., McHenry, M. B., Lok, K. H., Hunter, S. J., Le, N., Jenkins, A. J., Zheng, D., Semler, A. J., Brown, W. V., Lyons, T. J., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2004.05.004 · Cited by 33
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it
Xiong, X., Liu, H., Hua, L., Zhao, H., Wang, D., & Li, Y. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0129-8 · Cited by 31
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
Self-citation
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia
West, M. S., Herd, J. A., Ballantyne, C. M., Pownall, H. J., Simpson, S., Gould, K. L., & Gotto, A. M. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00178-x · Cited by 30
Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D
Basu, A., Bebu, I., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Budoff, M. J., Alaupovic, P., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p090647 · Cited by 30
Self-citation
The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial
Alaupovic, P., Fesmire, J. D., Hunnighake, D., DOMANSKI, M. J., Forman, S. A., Knatterud, G. L., Forrester, J. S., Herd, J. A., Hoogwerf, B. J., CAMPEAU, L. A., et al. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00151-3 · Cited by 30
Self-citation
Interaction of the common apolipoprotein C-III (APOC3 -482C > T) and hepatic lipase (LIPC -514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARS-II).
Jansen, H., Waterworth, D. M., Nicaud, V., Ehnholm, C., & Talmud, P. J. (2001) · PubMed · doi:10.1017/s0003480001008612 · Cited by 30
The effect of decreasing renal function on lipoprotein profiles
Attman, P.-O., Samuelsson, O. G., & Alaupovic, P. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq762 · Cited by 29
Self-citation
Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph
Fei, W., Kohan, A. B., Dong, H. H., Yang, Q., Xu, M., Huesman, S., Lou, D., Hui, D. Y., & Tso, P. (2014) · Physiological Reports · doi:10.1002/phy2.247 · Cited by 31
Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case–control study
Hopkins, P. N., Nanjee, M. N., Wu, L. L., McGinty, M. G., Brinton, E. A., Hunt, S. C., & Anderson, J. L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.016 · Cited by 29
Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE
Cohn, J. S., Rodriguez, C., Jacques, H., Tremblay, M., & Davignon, J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.d300041-jlr200 · Cited by 31
Negative and independent influence of apolipoprotein E on C-reactive protein (CRP) concentration in obese adults. Potential anti-inflammatory role of apoE in vivo
Bach‐Ngohou, K., Nazih, H., Nazih‐Sanderson, F., Zaïr, Y., Carrer, D. L., Krempf, M., & Bard, J. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801833 · Cited by 29
HDL Heterogeneity and Atherosclerosis
Tailleux, A., Fruchart, J., & Parkes, J. G. (1996) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369609083060 · Cited by 29
Relation Between Hemostatic Variables and Increase of Common Carotid Intima-Media Thickness in Patients With Peripheral Arterial Disease
Cortellaro, M., Baldassarre, D., Cofrancesco, E., Tremoli, E., Colombo, A. I. M., Boschetti, C., & Paoletti, R. (1996) · Stroke · doi:10.1161/01.str.27.3.450 · Cited by 29
Lipids, Apolipoproteins and Lipoproteins
Rader, D. J., & Brewer, H. B. (1994) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-1130-0_6 · Cited by 27
Retardation of Coronary Atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Other Angiographic Trials
de Faire, U., Ericsson, C., Grip, L., Nilsson, J., Svane, B., & Hamsten, A. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007787713191 · Cited by 21
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia
Ooi, T. C. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.10.016 · Cited by 27
Symposium on regression of atherosclerosis
Moncada, S., Martin, J., & Higgs, A. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb00781.x · Cited by 27
Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case–control study
Gerber, Y., Goldbourt, U., Segev, S., & Harats, D. (2003) · Preventive Medicine · doi:10.1016/s0091-7435(03)00051-3 · Cited by 24
Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease
Brunzell, J. D., & Hokanson, J. E. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00139-4 · Cited by 25
Inhibition of ApoCIII
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 24
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families
Bochem, A. E., van Capelleveen, J. C., Dallinga‐Thie, G. M., Schimmel, A. W. M., Motazacker, M. M., Tietjen, I., Singaraja, R. R., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., et al. (2013) · Clinical Genetics · doi:10.1111/cge.12201 · Cited by 26
Interaction of the common apolipoprotein C‐III (APOC3 ‐482C > T) and hepatic lipase (LIPC ‐514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARS‐II)
Jansen, H., Waterworth, D. M., Nicaud, V., Ehnholm, C., & Talmud, P. J. (2001) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2001.6530237.x · Cited by 24
Dyslipidemia and coronary artery disease
Kuo, P. T. (1994) · Clinical Cardiology · doi:10.1002/clc.4960171003 · Cited by 23
Hypertriglyceridemia and Coronary Heart Disease
Oberman, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.6.2098 · Cited by 22
Treatment strategies for management of serum lipids: Lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors
Rubenfire, M., COLETTI, A., & Mosca, L. J. (1998) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(98)80007-8 · Cited by 24
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery
Syvänne, M., Taskinen, M., Nieminen, M. S., Manninen, V., Kesäniemi, Y. A., Pasternack, A. I., Nawrocki, J. W., Haber, H. E., & Frick, M. H. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00091-8 · Cited by 22
Lipoprotein classes and coronary disease regression
Zambon, A., & Hokanson, J. E. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199808000-00008 · Cited by 22
Omega-3 Ethyl Ester Concentrate Decreases Total Apolipoprotein CIII and Increases Antithrombin III in Postmyocardial Infarction Patients
Swahn, E., von Schenck, H., & OLSSON, A. G. (1998) · Clinical Drug Investigation · doi:10.2165/00044011-199815060-00003 · Cited by 21
ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth
Blackett, P. R., Blevins, K. S., Quintana, E., Stoddart, M. L., Wang, W., Alaupovic, P., & Lee, E. T. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.010 · Cited by 21
Self-citation
Cardiovascular risk beyond LDL-C levels
Nash, D. T. (2004) · Postgraduate Medicine · doi:10.3810/pgm.2004.09.1584 · Cited by 20
Non-high-density lipoprotein cholesterol and cardiovascular disease
Bittner, V. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200308000-00005 · Cited by 20
Lipoprotein abnormalities in hirsute women II. Compensatory responses of insulin resistance and dehydroepiandrosterone sulfate with obesity
Wild, R. A., Alaupovic, P., Givens, J. R., & Parker, I. J. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91780-e · Cited by 19
Self-citation
HDL heterogeneity and coronary heart disease
Fiévet, C., & Fruchart, J. (1991) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610070304 · Cited by 19
Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women
Anderson, P. W., Cox, D. A., Sashegyi, A. I., Paul, S., Silfen, S. L., & Walsh, B. W. (2001) · Maturitas · doi:10.1016/s0378-5122(00)00224-3 · Cited by 19
Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency
Alaupovic, P., Attman, P.-O., Knight‐Gibson, C., Mulec, H., Weiss, L. G., & Samuelsson, O. G. (2006) · Kidney International · doi:10.1038/sj.ki.5000327 · Cited by 18
Self-citation
Non‐High‐Density Lipoprotein Cholesterol: An Alternate Target for Lipid‐Lowering Therapy
Bittner, V. (2004) · Preventive Cardiology · doi:10.1111/j.1520-037x.2004.3094.x · Cited by 18
Lipid risk factors and the regression of atherosclerosis.
Gotto, A. (1995) · American Journal of Cardiology · doi:10.1016/s0002-9149(05)80009-8 · Cited by 22
The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
Herd, J. (1998) · American Journal of Medicine · doi:10.1016/s0002-9343(98)00187-9 · Cited by 17
Apolipoprotein B–containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis
Knowlton, N. S., Wages, J., Centola, M. B., Giles, J. T., Bathon, J. M., Quiroga, C., & Alaupovic, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21646 · Cited by 17
Self-citation
Effect of milk fat on LDL cholesterol and other cardiovascular risk markers in healthy humans: the INNOVALAIT project
Bard, J., Drouet, L. O., Lairon, D., Cazaubiel, M., Marmonier, C., Ninio, E., Sollier, C. B. D., Martin, J., Boyer, C., Bobin‐Dubigeon, C., et al. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-019-0528-4 · Cited by 18
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020932 · Cited by 16
Antiretroviral therapy in HIV‐positive men is associated with increased apolipoprotein CIII in triglyceride‐rich lipoproteins
Rimland, D., Guest, J., Hernández, I., del Rı́o, C., Le, N., & Brown, W. V. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00316.x · Cited by 17
Thrombophilia in Patients with Hypertriglyceridemia
Chan, P., Huang, T.-Y., Shieh, S., Lin, T., & Tsai, C.-W. (1997) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1008857618659 · Cited by 17
The apolipoprotein ε2 allele and the severity of coronary artery disease in Type 2 diabetic patients
Kalix, B., Brulhart‐Meynet, M., Garin, M. C., & James, R. W. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00497.x · Cited by 16
Abnormalities of lipoprotein composition in renal insufficiency
Attman, P.-O., & Alaupovic, P. (1991) · Progress in Lipid Research · doi:10.1016/0163-7827(91)90025-z · Cited by 16
Self-citation
Are triglyceride-rich lipoproteins associated with aortic valve sclerosis? A preliminary report
Gerber, Y. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00292-2 · Cited by 16
Interrelationships between postprandial lipoprotein B:CIII particle changes and high-density lipoprotein subpopulation profiles in mixed hyperlipoproteinemia
Saïdi, Y., Sich, D., Camproux, A., Egloff, M., Federspiel, M.-C., Gautier, V., Raisonnier, A., Turpin, G., & Beucler, I. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90011-2 · Cited by 16
Hyperlipoproteinaemia in renal failure: pathogenesis and perspectives for intervention
Attman, P. (1993) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a092458 · Cited by 15
Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development
Orloff, D. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01423-0 · Cited by 15
ApoB-Containing Lipoprotein Particles as Risk Factors for Coronary Artery Disease
Alaupovic, P., Blackenhorn, D. H., Knight‐Gibson, C., Tavella, M. J., Bard, J., Shafer, D., Lee, E. T., & Brasuell, J. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5904-3_36 · Cited by 15
Self-citation
Relationship between apolipoprotein C-III concentrations and high-density lipoprotein subclass distribution
Tian, L., Wu, J., Fu, M., Xu, Y., & Jia, L. (2009) · Metabolism · doi:10.1016/j.metabol.2009.01.007 · Cited by 14
Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent
Kramsch, D. M. (1997) · International Journal of Cardiology · doi:10.1016/s0167-5273(97)00249-0 · Cited by 15
Comparative clinical consequences of aggressive lipid management, coronary angioplasty and bypass surgery in coronary artery disease
Vogel, R. A. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90941-q · Cited by 14
Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709)
Kulik, A., Abreu, A. M., Boronat, V., & Ruel, M. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.006 · Cited by 13
Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease resulting from alcohol abuse: effects of alcohol intake cessation
Camps, J., Pizarro, I., Prats, E., Ville, A. L., TURNER, P. R., Masana, L., & Joven, J. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80227-0 · Cited by 13
Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper
Colivicchi, F., Fusco, S. A. D., Arca, M., Leggio, M., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001175 · Cited by 13
Nicotinic Acid and Derivatives
OLSSON, A. G. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78426-2_13 · Cited by 12
Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coronary artery bypass operation
Voors, A. A., van Brüssel, B. L., Kelder, J. C., & Plokker, H. W. T. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00138-0 · Cited by 12
Atherosclerotic Risks from Chemicals: Part I. Toxicological Observations and Mechanisms of Atherosclerosis
Basavaraju, S. R., & Jones, T. D. (1998) · Archives of Environmental Contamination and Toxicology · doi:10.1007/s002449900363 · Cited by 12
LESSONS FROM CORONARY ATHEROSCLEROSIS "REGRESSION" TRIALS
Waters, D. D. (1996) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70259-9 · Cited by 10
Prevention of coronary heart disease Part I. Primary prevention
Liesbon, P. R., & Amsterdam, E. A. (1999) · Disease-a-Month · doi:10.1016/s0011-5029(99)90016-0 · Cited by 11
Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes
Wang, W., Khan, S. H., Blackett, P. R., Alaupovic, P., & Lee, E. T. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.06.007 · Cited by 11
Self-citation
Apolipoprotein-defined lipoproteins and apolipoproteins: Associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort
Jenkins, A. J., Yu, Y., Alaupovic, P., Basu, A., Klein, R. L., Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., Lackland, D. T., Garvey, W. T., et al. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.002 · Cited by 11
Self-citation
Characterization of the Metabolic Syndrome by Apolipoproteins in the Oklahoma Cherokee
Alaupovic, P., Blackett, P. R., Wang, W., & Lee, E. T. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00022.x · Cited by 11
Self-citation
Rosuvastatina para tratamiento de la dislipidemia en pacientes infectados con VIH en tratamiento antirretroviral de gran actividad. Experiencia preliminar
Bottaro, E. G., Caravello, Ó., Scapellato, P. G., Stambullian, M., Vidal, G. I., Loggia, V., Scapellato, J. L., Thompson, F., & Cassetti, I. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13123836 · Cited by 11
Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristics
Nielsen, N. E., OLSSON, A. G., & Swahn, E. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00567.x · Cited by 11
Association of angiographically detected coronary artery disease with low levels of high-density lipoprotein cholesterol and systemic hypertension
French, J. K., Elliott, J. M., Williams, B. F., Nixon, D. J., Denton, M. A., & White, H. D. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90503-5 · Cited by 11
Current and Future Therapeutic Approaches to Hyperlipidemia
Farmer, J. A., & Gotto, A. M. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60275-6 · Cited by 13
Prognostic and Therapeutic Significance of Low Levels of High-Density Lipoprotein Cholesterol
Gotto, A. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.10.1038 · Cited by 11
Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics
Larach, D. B., Cuchel, M., & Rader, D. J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.73 · Cited by 10
Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia
Dallongeville, J., Fruchart, J., Maigret, P., Bertolini, S., Bon, G. B., Campbell, M. M., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., et al. (1998) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849800300202 · Cited by 10
Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles.
Bekaert, E. D., Alaupovic, P., Knight‐Gibson, C., Franceschini, G., & Sirtori, C. R. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41325-2 · Cited by 10
Self-citation
Apolipoprotein C-III
Miller, M. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309493 · Cited by 10

Authors: Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P.
Affiliations: University of Southern California (US)
ORCID: Alaupovic, P
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1990-02
Volume: 81
Issue: 2
Pages: 470-476
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.81.2.470
OpenAlex: W2092138949
Cited by: 278
References: 32
Citations by year: 2026: 1 · 2025: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 6 · 2012: 6
FWCI: 22.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Oklahoma Medical Research Foundation
National Institutes of Health (5p01hl023619-10)
National Heart, Lung, and Blood Institute (HL 23619)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: coronary artery disease progression, aortocoronary bypass graft, native coronary arteries, colestipol, nicotinic acid, cholesterol-lowering therapy, risk factors, non-HDL cholesterol, apolipoprotein C-III, HDL cholesterol, triglyceride-rich lipoproteins, apolipoprotein B, LDL cholesterol, triglycerides, diastolic blood pressure, atherosclerosis regression
MeSH terms: Coronary Artery Bypass, Apolipoproteins, Apolipoproteins C, Colestipol, Coronary Artery Disease, Humans, Lipids, Male, Middle Aged, Niacin, Recurrence, Multivariate Analysis, Randomized Controlled Trials as Topic, Coronary Angiography, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks